drugset / Trial / NCT00133848

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

NCT00133848

Phase 3 Completed 210 enrolled GlaxoSmithKline
RandomizedDouble-blindTreatment

Summary

The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.

Timeline

Start
2005-04
Primary completion
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Retapamulin Small molecule 1 % Topical

Indications